Jung, Wolfram

[["dc.bibliographiccitation.firstpage","711"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Medical Education"],["dc.bibliographiccitation.lastpage","720"],["dc.bibliographiccitation.volume","50"],["dc.contributor.author","Raupach, Tobias"],["dc.contributor.author","Andresen, Jil C."],["dc.contributor.author","Meyer, Katharina"],["dc.contributor.author","Strobel, Lisa"],["dc.contributor.author","Koziolek, Michael"],["dc.contributor.author","Jung, Wolfram"],["dc.contributor.author","Brown, Jamie"],["dc.contributor.author","Anders, Sven"],["dc.date.accessioned","2018-11-07T10:12:24Z"],["dc.date.available","2018-11-07T10:12:24Z"],["dc.date.issued","2016"],["dc.description.abstract","ContextClinical reasoning is an essential skill, the foundations of which should be acquired during undergraduate medical education. Student performance in clinical reasoning can be assessed using key feature examinations. However, within a paradigm of test-enhanced learning, such examinations may also be used to enhance long-term retention ofprocedural knowledge relevant to clinical reasoning. ObjectivesThis study tested the hypothesis that repeated testing with key feature questions is more effective than repeated case-based learning in fostering clinical reasoning. MethodsIn this randomised crossover trial, Year4 medical students attended 10 weekly computer-based seminars during which patient case histories covering general medical conditions were displayed. The presentation format was switched between groups every week. In the control condition, students studied long case narratives. The intervention condition used the same content but augmented case presentation with a sequence of key feature questions. Using a within-subjects design, student performance on intervention and control items was assessed at 13weeks (exit examination) and 9months (retention test) after the first day of term. ResultsA total of 87 of 124 eligible students provided complete data for the longitudinal analysis (response rate: 70.2%). In the retention test, meanstandard deviation student scores on intervention items were significantly higher than those on control items (56.025.8% versus 48.8 +/- 24.7%; p<0.001). The results remained unchanged after accounting for exposure time in a linear regression analysis that also adjusted for sex and general student performance levels. ConclusionsThis is the first study to demonstrate an effect of test-enhanced learning on clinical reasoning as assessed with key feature questions. In this randomised trial, repeated testing was more effective than repeated case-based learning alone. Curricular implementation of longitudinal key feature testing may considerably enhance student learning outcomes in relevant aspects of clinical medicine."],["dc.identifier.doi","10.1111/medu.13069"],["dc.identifier.isi","000378731000006"],["dc.identifier.pmid","27295475"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40228"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1365-2923"],["dc.relation.issn","0308-0110"],["dc.title","Test-enhanced learning of clinical reasoning: a crossover randomised trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2763"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.lastpage","2767"],["dc.bibliographiccitation.volume","102"],["dc.contributor.author","Fiedler, Walter"],["dc.contributor.author","Mesters, R."],["dc.contributor.author","Tinnefeld, H."],["dc.contributor.author","Loges, S."],["dc.contributor.author","Staib, Peter"],["dc.contributor.author","Duhrsen, U."],["dc.contributor.author","Flasshove, M."],["dc.contributor.author","Ottmann, Oliver G."],["dc.contributor.author","Jung, W. F."],["dc.contributor.author","Cavalli, F."],["dc.contributor.author","Kuse, R."],["dc.contributor.author","Thomalla, J."],["dc.contributor.author","Serve, Hubert"],["dc.contributor.author","O'Farrell, A. M."],["dc.contributor.author","Jacobs, M."],["dc.contributor.author","Brega, N. M."],["dc.contributor.author","Scigalla, P."],["dc.contributor.author","Hossfeld, D. K."],["dc.contributor.author","Berdel, Wolfgang E."],["dc.date.accessioned","2018-11-07T10:35:28Z"],["dc.date.available","2018-11-07T10:35:28Z"],["dc.date.issued","2003"],["dc.description.abstract","Neoangiogenesis has been shown to play an important role in the pathogenesis of acute myeloid leukemia (AML). Autocrine and paracrine secretion of angiogenic and hematopoietic growth factors such as vascular endothelial growth factor (VEGF) and stem cell factor (SCF) in the bone marrow microenvironment may promote proliferation and survival of leukemic blasts. This concept represented the rationale for the initiation of a multicenter phase 2 trial of SU5416, a small molecule inhibitor of phosphorylation of VEGF receptors 1 and 2, c-kit, the SCIF receptor, and fms-like tyrosine kinase-3 (FLT3) in patients with advanced AML. Entered into the study were 43 patients with refractory AML or elderly patients not judged medically fit for intensive induction chemotherapy; 42 patients received at least one dose of study drug. Treatment was generally well tolerated, with nausea, headache, and bone pain the most frequent treatment-related side effects. One patient had a morphologic remission (French-American-British [FAB] criteria of complete response without normalization of blood neutrophil and platelet counts) lasting for 2 months. There were 7 patients who achieved a partial response (reduction of blasts by at least 50% in bone marrow and peripheral blood) lasting 1 to 5 months. Patients with AML blasts expressing high levels of VEGF mRNA by quantitative polymerase chain reaction (PCR) had a significantly higher response rate and reduction of bone marrow microvessel density than patients with low VEGF expression consistent with the antiangiogenic effects of SU5416. (C) 2003 by The American Society of Hematology."],["dc.identifier.doi","10.1182/blood-2002-10-2998"],["dc.identifier.isi","000185877300019"],["dc.identifier.pmid","12843001"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/45106"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","0006-4971"],["dc.title","A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2476"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Leukemia & Lymphoma"],["dc.bibliographiccitation.lastpage","2480"],["dc.bibliographiccitation.volume","57"],["dc.contributor.author","Shumilov, Evgenii"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Hellige, Niels"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Jung, Wolfram"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Binder, Mascha"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Bacher, Ulrike"],["dc.date.accessioned","2020-12-10T18:43:56Z"],["dc.date.available","2020-12-10T18:43:56Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.3109/10428194.2016.1151510"],["dc.identifier.eissn","1029-2403"],["dc.identifier.issn","1042-8194"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78273"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Osteolytic lesions occur rarely in patients with B-CLL and may respond well to ibrutinib"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","59"],["dc.bibliographiccitation.issue","22"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.lastpage","60"],["dc.bibliographiccitation.volume","114"],["dc.contributor.author","Einsele, Hermann"],["dc.contributor.author","Liebisch, Peter"],["dc.contributor.author","Langer, Christian"],["dc.contributor.author","Kropff, Martin H."],["dc.contributor.author","Wandt, Hannes"],["dc.contributor.author","Jung, Wolfram"],["dc.contributor.author","Kroeger, Nicolaus M."],["dc.contributor.author","Engelhardt, Monika"],["dc.contributor.author","Ostermann, Helmut"],["dc.contributor.author","Muegge, Lars-Olof"],["dc.contributor.author","Wolf, Hans-Heinrich"],["dc.contributor.author","Hart, Christina"],["dc.contributor.author","Metzner, Bernd"],["dc.contributor.author","Kaufmann, Martin"],["dc.contributor.author","Gramatzki, Martin"],["dc.contributor.author","Hertenstein, Bernd"],["dc.contributor.author","Fischer, Thomas"],["dc.contributor.author","Weisel, Katja"],["dc.contributor.author","Doelken, Gottfried"],["dc.contributor.author","Brugger, Wolfram"],["dc.contributor.author","Gollasch, Hella"],["dc.contributor.author","Maschmeyer, Georg"],["dc.contributor.author","Pfreundschuh, Michael"],["dc.contributor.author","Schmitz, Norbert"],["dc.contributor.author","Sezer, Orhan"],["dc.contributor.author","Heidemann, Else"],["dc.contributor.author","Jaeger, Elke"],["dc.contributor.author","Kahl, Christoph"],["dc.contributor.author","Kiani, Alexander"],["dc.contributor.author","Dechow, Tobias"],["dc.contributor.author","Roesler, Wolf"],["dc.contributor.author","Simon, Jan Philipp"],["dc.contributor.author","Duerk, Heinz"],["dc.contributor.author","Pflueger, Karl Heinz"],["dc.contributor.author","Bentz, Martin"],["dc.contributor.author","Hess, Georg"],["dc.contributor.author","Mergenthaler, Hans-Guenther"],["dc.contributor.author","Straka, Christian"],["dc.contributor.author","Hempel, Dirk"],["dc.contributor.author","Salwender, Hans-Juergen"],["dc.contributor.author","Fingerle-Rowson, Guenter"],["dc.contributor.author","Knop, Stefan"],["dc.date.accessioned","2018-11-07T11:21:53Z"],["dc.date.available","2018-11-07T11:21:53Z"],["dc.date.issued","2009"],["dc.identifier.isi","000272725800132"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/55885"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.publisher.place","Washington"],["dc.relation.conference","51st Annual Meeting of the American-Society-of-Hematology"],["dc.relation.eventlocation","New Orleans, LA"],["dc.relation.issn","0006-4971"],["dc.title","Velcade, Intravenous Cyclophosphamide and Dexamethasone (VCD) Induction for Previously Untreated Multiple Myeloma (German DSMM XIa Trial)"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","218"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Scandinavian Journal of Immunology"],["dc.bibliographiccitation.lastpage","229"],["dc.bibliographiccitation.volume","67"],["dc.contributor.author","Hasenkamp, J."],["dc.contributor.author","Borgerding, A."],["dc.contributor.author","Uhrberg, M."],["dc.contributor.author","Falk, C."],["dc.contributor.author","Chapuy, Björn"],["dc.contributor.author","Wulf, G."],["dc.contributor.author","Jung, W."],["dc.contributor.author","Trümper, L."],["dc.contributor.author","Glass, B."],["dc.date.accessioned","2021-06-01T10:47:17Z"],["dc.date.available","2021-06-01T10:47:17Z"],["dc.date.issued","2008"],["dc.identifier.doi","10.1111/j.1365-3083.2007.02058.x"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85548"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","1365-3083"],["dc.relation.issn","0300-9475"],["dc.title","Self-tolerance of Human Natural Killer Cells Lacking Self-HLA-specific Inhibitory Receptors"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","31"],["dc.bibliographiccitation.issue","Supplement 1"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.lastpage","31"],["dc.bibliographiccitation.volume","132"],["dc.contributor.author","Ottmann, Oliver G."],["dc.contributor.author","Pfeifer, Heike"],["dc.contributor.author","Cayuela, Jean-Michel"],["dc.contributor.author","Spiekermann, Karsten"],["dc.contributor.author","Jung, Wolfram"],["dc.contributor.author","Beck, Joachim"],["dc.contributor.author","Raffoux, Emmanuel"],["dc.contributor.author","Turlure, Pascal"],["dc.contributor.author","Himberlin, Chantal"],["dc.contributor.author","Huguet, Francoise"],["dc.contributor.author","Viardot, Andreas"],["dc.contributor.author","Wendelin, Knut"],["dc.contributor.author","Reichle, Albrecht"],["dc.contributor.author","Maury, Sébastien"],["dc.contributor.author","Sanhes, Laurence"],["dc.contributor.author","Isnard, Francoise"],["dc.contributor.author","Cahn, Jean-Yves"],["dc.contributor.author","Lepretre, Stephane"],["dc.contributor.author","Chevallier, Patrice"],["dc.contributor.author","Escoffre-Barbe, Martine"],["dc.contributor.author","Ribera, Josep-Maria"],["dc.contributor.author","Hoelzer, Dieter"],["dc.contributor.author","Goekbuget, Nicola"],["dc.contributor.author","Dombret, Hervé"],["dc.contributor.author","Rousselot, Philippe"],["dc.date.accessioned","2020-12-10T18:38:45Z"],["dc.date.available","2020-12-10T18:38:45Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1182/blood-2018-99-114552"],["dc.identifier.eissn","1528-0020"],["dc.identifier.issn","0006-4971"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77427"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Nilotinib (Tasigna®) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1-Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3637"],["dc.bibliographiccitation.issue","13"],["dc.bibliographiccitation.journal","Clinical Cancer Research"],["dc.bibliographiccitation.lastpage","3647"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Heemann, Christina"],["dc.contributor.author","Kreuz, Markus"],["dc.contributor.author","Stoller, Irene"],["dc.contributor.author","Schoof, Nils"],["dc.contributor.author","von Bonin, Frederike"],["dc.contributor.author","Ziepert, Marita"],["dc.contributor.author","Loeffler, Markus"],["dc.contributor.author","Jung, Wolfram"],["dc.contributor.author","Pfreundschuh, Michael"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Kube, Dieter"],["dc.date.accessioned","2018-11-07T09:08:22Z"],["dc.date.available","2018-11-07T09:08:22Z"],["dc.date.issued","2012"],["dc.description.abstract","Purpose: Peripheral T-cell non-Hodgkin lymphomas (T-NHL) represent a small but heterogeneous and clinically aggressive subset of NHLs with a poor outcome. Cytokines or their receptors might be associated with the clinical outcome of these lymphomas. Therefore, we tested whether gene variations and serum levels of soluble TNF receptor (TNFR)I (sTNFRI), sTNFRII, interleukin (IL)-10, or sIL-4R are predictive for treatment response in T-NHLs. Experimental Design: Peripheral blood DNA from 117 patients with T-NHL treated in prospective clinical trials was subjected to genotyping analysis. Whenever possible, pretreatment sera were obtained, and circulating levels of sTNFRI, sTNFRII, IL-10, and sIL-4R were determined with a specific capture enzyme-linked immunoassay. Results: Patients characterized by TNFRI-609GG (rs4149570) showed a trend toward better event free survival [EFS; univariate: P = 0.041; multivariate: HR, 1.76; confidence interval (CI), 0.99-3.14 with P = 0.056]. A protective role of IL-10-1087A, -824T, and -597A reported in another study was not confirmed in our cohort. Patients with circulating levels of soluble TNFRII >= 2.16 ng/mL had a 2.07-fold increased relative risk for shorter overall survival (OS; univariate: P = 0.0034; multivariate: HR, 2.07; CI, 0.92-4.70 with P = 0.081) and a 2.49-fold higher risk for shorter EFS (univariate: P = 0.00068; multivariate: HR, 2.49; CI, 1.22-5.08 with P = 0.012). Elevations of circulating levels of sTNFRI, IL-10, and sIL-4R are frequent, but the clinical response in these patients is not significantly different. Conclusions: Our findings suggest a critical role for TNF-TNFR signaling for the clinical outcome of patients with peripheral T-NHLs. Clin Cancer Res; 18(13); 3637-47. (C)2012 AACR."],["dc.identifier.doi","10.1158/1078-0432.CCR-11-3299"],["dc.identifier.isi","000307502600016"],["dc.identifier.pmid","22573350"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26018"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Assoc Cancer Research"],["dc.relation.issn","1078-0432"],["dc.title","Circulating Levels of TNF Receptor II Are Prognostic for Patients with Peripheral T-cell Non-Hodgkin Lymphoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","ejh.13690"],["dc.bibliographiccitation.journal","European Journal of Haematology"],["dc.contributor.author","Straka, Christian"],["dc.contributor.author","Salwender, Hans"],["dc.contributor.author","Knop, Stefan"],["dc.contributor.author","Vogel, Martin"],["dc.contributor.author","Müller, Jürgen"],["dc.contributor.author","Metzner, Bernd"],["dc.contributor.author","Langer, Christian"],["dc.contributor.author","Sayer, Herbert"],["dc.contributor.author","Jung, Wolfram"],["dc.contributor.author","Dürk, Heinz A."],["dc.contributor.author","Einsele, Hermann"],["dc.date.accessioned","2021-10-01T09:58:01Z"],["dc.date.available","2021-10-01T09:58:01Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.1111/ejh.13690"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/89968"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-469"],["dc.relation.eissn","1600-0609"],["dc.relation.issn","0902-4441"],["dc.title","Full or intensity‐reduced high‐dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e462"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","The Lancet Haematology"],["dc.bibliographiccitation.lastpage","e473"],["dc.bibliographiccitation.volume","5"],["dc.contributor.author","von Tresckow, Bastian"],["dc.contributor.author","Kreissl, Stefanie"],["dc.contributor.author","Goergen, Helen"],["dc.contributor.author","Bröckelmann, Paul J"],["dc.contributor.author","Pabst, Thomas"],["dc.contributor.author","Fridrik, Michael"],["dc.contributor.author","Rummel, Mathias"],["dc.contributor.author","Jung, Wolfram"],["dc.contributor.author","Thiemer, Julia"],["dc.contributor.author","Sasse, Stephanie"],["dc.contributor.author","Bürkle, Carolin"],["dc.contributor.author","Baues, Christian"],["dc.contributor.author","Diehl, Volker"],["dc.contributor.author","Engert, Andreas"],["dc.contributor.author","Borchmann, Peter"],["dc.date.accessioned","2020-12-10T15:22:09Z"],["dc.date.available","2020-12-10T15:22:09Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1016/S2352-3026(18)30140-6"],["dc.identifier.issn","2352-3026"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/73287"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","4121"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Anticancer Research"],["dc.bibliographiccitation.lastpage","4125"],["dc.bibliographiccitation.volume","24"],["dc.contributor.author","Strik, Herwig M."],["dc.contributor.author","Spreer, Annette"],["dc.contributor.author","Nagel, Holger"],["dc.contributor.author","Jacob, Sonja"],["dc.contributor.author","Jung, Wolfram"],["dc.contributor.author","Kitze, Bernd"],["dc.contributor.author","Bähr, Mathias"],["dc.date.accessioned","2017-09-07T11:43:10Z"],["dc.date.available","2017-09-07T11:43:10Z"],["dc.date.issued","2004"],["dc.description.abstract","A 69-year-old female patient was treated for primary CNS-lymphoma (PCNSL) starting from August 2002. As her general condition allowed no high-dose methotrexate (MTX) therapy, radiotherapy was administered as a first-line treatment. CSF involvement could be managed by intrathecal Ara-C. Her general condition and cognitive status stabilized., but did not improve for 3 months. Therefore, oral chemotherapy with Temozolomide 200mg/m(2) was initiated. After two courses, which were tolerated without any problems, the patient's Karnofsky performance index had improved from 40% to 50%, the Mini-Mental Status rose from 16 to 27130. The CSF-cell count was elevated again to 23 cells/mul without signs of meningeal relapse. Unfortunately, the patient died unexpectedly front suspected pulmonary embolism. We conclude that adjuvant Temozolomide chemotherapy can improve the general condition and cognition in patients with PCNSL even when the general condition is poor. Long-term effects and neurotoxicity remain to be analysed in prospective trials, as well as the efficacy in leptomeningeal disease."],["dc.identifier.gro","3143931"],["dc.identifier.isi","000227014500066"],["dc.identifier.pmid","15736462"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/1499"],["dc.language.iso","en"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.issn","0250-7005"],["dc.title","Clinical Response Following Adjuvant Temozolomide in a Patient with Primary Cerebral Lymphoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]